February 23, 2017 4:32 PM ET


Company Overview of Khandelwal Laboratories Pvt.Ltd.

Company Overview

Khandelwal Laboratories Pvt.Ltd. manufactures and markets oncology products. It offers ANAFORTAN Group, a combination with camylofin DiHCl antispasmodic; ROBI Group, a combination with methocarbamol muscle relaxants; CEFI Group, a combination of cefixime antibiotic; and PRENOXID, a prenoxdiazine HCl antitussive. The company also provides generic products anaesthetics, anthelmintic, anti hypertensives, anti-ulcler agents, anti-asthamatic, anti-diabetic, anti-fungal, anti-histamines, anti-microbials, anti-tussives, drugs in osteoporosis, haematinic and nutritional supplement, NSAIDs, and skeletal muscle relaxants. In addition, it offers chiral intermediates, including monosaccharides derivativ...

79/87 D.Ladpath

Mumbai,  400 033


Founded in 1945


91 22 2371 8238


91 22 2373 9381

Key Executives for Khandelwal Laboratories Pvt.Ltd.

Chairman of the Board and Managing Director
Whole time Director
Compensation as of Fiscal Year 2016.

Khandelwal Laboratories Pvt.Ltd. Key Developments

Khandelwal Laboratories Receives Approval of the Product Licenses for Zestra Zestra Glide, Ejectdelay and Sensum from the Indian FDA

Khandelwal Laboratories announced that its has received the approval of the product licenses for Zestra Zestra Glide, EjectDelay and Sensum from the Indian FDA, The Drugs Controller General (India), and the Directorate General of Health Services to commercialize the products in India. Zestra is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra is the first Natural Health Product to receive approval for the indication of FSI/AD in Canada as an NHP.

Innovus Pharmaceuticals, Inc. Enters into Marketing and Distribution Agreement with Khandelwal Laboratories

Innovus Pharmaceuticals, Inc. announced it has entered into an marketing and distribution agreement with Khandelwal Laboratories under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell Innovus Pharma’s products including Zestra® to increase Female Sexual Arousal, Desire and Satisfaction, EjectDelay® for treating premature ejaculation, Sensum+® to increase penile sensitivity and Zestra Glide® the high viscosity water based lubricant. If KLabs exceeds its minimum yearly orders, the agreement has two five-year term extensions. This deal has been facilitated by Nortons (UK). Under the agreement, the minimum orders for the first term of the agreement are over $2.6 million.

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Khandelwal Laboratories Pvt.Ltd., please visit www.khandelwallab.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.